<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0006919.ref044">
 <label>44</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ramsauer</surname>
   <given-names>K</given-names>
  </name>, 
  <name>
   <surname>Schwameis</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Firbas</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Mullner</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Putnak</surname>
   <given-names>RJ</given-names>
  </name>, 
  <name>
   <surname>Thomas</surname>
   <given-names>SJ</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial</article-title>. 
  <source>Lancet infect Dis</source>. 
  <year>2015</year> Epub 2015/03/06. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(15)70043-5</pub-id> .
  <?supplied-pmid 25739878?>
  <pub-id pub-id-type="pmid">25739878</pub-id>
 </mixed-citation>
</ref>
